Clinical Study of Fruquintinib Combined With Raltitrexed in the Treatment of Metastatic Colorectal Cancer
Status:
Recruiting
Trial end date:
2026-10-01
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy and safety of Fruquintinib combined with Raltitrexed in the
treatment of metastatic colorectal cancer that progressed or could not be tolerated after
previous fluorouracil, oxaliplatin, and irinotecan based therapy
Phase:
Phase 4
Details
Lead Sponsor:
The First Affiliated Hospital of Nanchang University